NCT04155749 2026-02-11Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaGilead SciencesPhase 1 Active not recruiting40 enrolled
NCT04649359 2025-12-02MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAbPfizerPhase 2 Active not recruiting187 enrolled 14 charts 2 FDA
NCT03162536 2025-09-08ARQ 531-101ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Phase 1/2 Active not recruiting190 enrolled
NCT02899052 2025-08-05Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)AbbViePhase 2 Active not recruiting120 enrolled
NCT04354246 2025-05-22COM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesCompugen LtdPhase 1 Active not recruiting110 enrolled
NCT04782687 2025-01-16Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaUS Oncology ResearchPhase 2 Active not recruiting73 enrolled